AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Celldex Therapeutics, Inc.
Video analysis: CLDX
All videosNo video analysis for this stock yet. Request one from our team.
News: CLDX
Celldex to Present at Upcoming Investor Conference
HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
California State Teachers Retirement System Acquires 21,233 Shares of Celldex Therapeutics, Inc. $CLDX
California State Teachers Retirement System raised its holdings in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 36.4% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 79,630 shares of the biopharmaceutical company's stock after buying an additional 21,233 shares during the quarter. California State
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex Therapeutics (NASDAQ: CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies. Anthony Marucci, Celldex's co-founder, president and chief executive officer, said the company was
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday said it is ending its Phase 2 clinical trial evaluating barzolvolimab for prurigo nodularis, a chronic condition characterized by intensely itchy skin nodules.
